ArticleBMC infectious diseases2025
The impact of pt-NGS technology on antimicrobial use and outcomes in patients with lower respiratory tract infections: a hospital-based real-world study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the impact of pathogen-targeted next-generation sequencing (pt-NGS) technology on antimicrobial use and clinical outcomes in hospitalized adults with lower respiratory tract infections (LRTIs).
methodsIn this retrospective cohort study, 340 adult LRTI patients were stratified into two groups: a pt-NGS-guided group (n = 140) and a conventional microbiological testing-guided group (n = 200). Outcomes included pathogen detection rates, antimicrobial therapy adjustments, clinical outcomes (mortality, length of stay LOS, ICU admission), and healthcare costs. Statistical analyses utilized t-tests, Mann-Whitney U tests, and multivariable regression.
resultsThe pt-NGS group exhibited significantly higher pathogen detection rates (90.9%vs. 52.5%, P < 0.001) and a greater proportion of antimicrobial regimen adjustments (38.0%vs.16.7%, P = 0.013). Clinically, the pt-NGS group exhibited a shorter median duration of inappropriate antibiotic therapy (3.5vs.6days, P = 0.012), reduced hospital LOS and costs(23vs.38days, P = 0.024)/(CN¥26,548 vs. CN¥31,827, P = 0.026),and lower ICU admission rates (30.1% vs. 49.6%, P = 0.016), Mortality did not differ significantly between groups (4.68% vs. 6.10%, P = 0.382).
conclusionpt-NGS technology enhances diagnostic precision, accelerates targeted antimicrobial therapy, and reduces unnecessary broad-spectrum antibiotic exposure, thereby improving clinical outcomes and resource utilization in LRTI management. Notably, no significant mortality benefit was observed, and broad-spectrum antimicrobial use increased in the pt-NGS group. These findings underscore its potential as a valuable tool supporting of antimicrobial stewardship programs in severe respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.